The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index; 8 of the 18 sources its claims cite were checked for support.
Teclistamab in Relapsed or Refractory Multiple Myeloma
Open accessAbstract
BACKGROUND: Teclistamab is a T-cell-redirecting bispecific antibody that targets both CD3 expressed on the surface of T cells and B-cell maturation antigen expressed on the surface of myeloma cells. In the phase 1 dose-defining portion of the study, teclistamab showed promising efficacy in patients with relapsed or refractory multiple myeloma. METHODS: In this phase 1-2 study, we enrolled patients who had relapsed or refractory myeloma after at least three therapy lines, including triple-class exposure to an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody. Patients received a weekly subcutaneous injection of teclistamab (at a dose of 1.5 mg per kilogram of body weight) after receiving step-up doses of 0.06 mg and 0.3 mg per kilogram. The primary end point was the overall response (partial response or better). RESULTS: Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines). With a median follow-up of 14.1 months, the overall response rate was 63.0%, with 65 patients (39.4%) having a complete response or better. A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD); the MRD-negativity rate among the patients with a complete response or better was 46%. The median duration of response was 18.4 months (95% confidence interval [CI], 14.9 to not estimable). The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1). Common adverse events included cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4), neutropenia (in 70.9%; grade 3 or 4, 64.2%), anemia (in 52.1%; grade 3 or 4, 37.0%), and thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%). Infections were frequent (in 76.4%; grade 3 or 4, 44.8%). Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell-associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2). CONCLUSIONS: Teclistamab resulted in a high rate of deep and durable response in patients with triple-class-exposed relapsed or refractory multiple myeloma. Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2. (Funded by Janssen Research and Development; MajesTEC-1 ClinicalTrials.gov numbers, NCT03145181 and NCT04557098.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
8 of 18 cited sources checked · 5 supported · 0 flagged · accuracy not yet measured
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“In contrast, higher-grade cytokine release syndrome and neurotoxic events have been described after CAR-T administration in patients with multiple myeloma.6,8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [6] source
Table 2 reports grade 3 or higher cytokine release syndrome in 7 of 128 patients and grade 3 neurotoxic effects in 4 of 128 after ide-cel infusion. The Methods identify the treated population as patients with relapsed and refractory multiple myeloma. (LLM, conf=0.93)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among 165 patients who received teclistamab, 77.6% had triple-class refractory disease (median, five previous therapy lines).”
- Also stated in: § PATIENTS · plain
“Before study entry, 148 patients (89.7%) had resistance to the previous line of therapy, 128 (77.6%) had triple-class refractory disease, and 50 (30.3%) had penta-drug refractory disease.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Responses occurred in 104 of 165 patients (63.0%; 95% confidence interval [CI], 55.2 to 70.4).”
- Also stated in: § RESULTS · plain
“the overall response rate was 63.0%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1)”
- Also stated in: § RESULTS · plain
“The median duration of progression-free survival was 11.3 months (95% CI, 8.8 to 17.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The Kaplan–Meier estimate of maintenance of response for at least 12 months was 68.5% (95% CI, 57.7 to 77.1).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Otherwise, response rates were consistent across most clinically relevant subgroups, including patients with high-risk cytogenetic abnormalities and those with penta-drug refractory disease (Fig. S2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Hypogammaglobulinemia occurred in 123 patients (74.5%) as determined by means of adverse-event reporting, laboratory analyses (IgG level, <500 mg per deciliter), or both”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 123Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among the 65 patients who had a complete response or better, 30 (46%) had no minimal residual disease (Table S4).”
- Also stated in: § RESULTS · plain
“the MRD-negativity rate among the patients with a complete response or better was 46%”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 65Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease (at a threshold of 10−5) was reported in 44 patients (26.7%; 95% CI, 20.1 to 34.1).”
- Also stated in: § RESULTS · plain
“A total of 44 patients (26.7%) were found to have no minimal residual disease (MRD)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“a complete response or better occurred in 65 (39.4%)”
- Also stated in: § RESULTS · plain
“65 patients (39.4%) having a complete response or better”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § RESULTS · plain
- It may state two separate claims as one. 31
- Probably not a substantial claim. 12
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“CAR-T therapy requires that patients have access to specialized care centers and can wait the minimum 4-week period for production, which can result in attrition rates of approximately 10 to 15%,6-8”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Partly supportedcites [6] sourceExperimental — accuracy not yet measured
The Patients section (page not available) reports that 12 of 140 enrolled patients discontinued before ide-cel infusion, an attrition rate of about 8.6%, and that some patients received bridging therapy during manufacturing. It does not establish a minimum four-week production period, a requirement for access to specialized care centers, or that waiting caused the discontinuations. (LLM, conf=0.85)
- Partly supportedcites [7] sourceExperimental — accuracy not yet measured
The Discussion and future perspectives section (page unavailable) says CAR T-cell treatment involves a specialized center and that manufacturing takes several days to weeks, during which disease may progress. It does not establish a minimum four-week production period or an attrition rate of approximately 10–15%. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [8] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Such absence of minimal residual disease has been associated with improved overall survival and progression-free survival in patients with myeloma.14-16”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [14] source
- Supportedcites [15] source
The Introduction states that MRD-negative status is associated with improved progression-free survival (PFS) and overall survival (OS). The Discussion likewise reports prior multiple-myeloma findings for both outcomes; the paper's own OS data were immature, but the claim does not attribute an OS result to this study's analysis. (LLM, conf=0.94)
- Supportedcites [16] source
The Discussion states that MRD negativity is associated with improved survival in both newly diagnosed and relapsed/refractory myeloma. The Introduction links MRD negativity with prolonged progression-free and overall survival, supporting both endpoints in the claim. (LLM, conf=0.90)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
Every source the paper cites for this claim was checked and supports it.
In the paper
“Adverse events were graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.03), except for cytokine release syndrome (Table S2) and immune effector cell–associated neurotoxicity syndrome, which were graded according to the criteria of the American Society for Transplantation and Cellular Therapy.12”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Supportedcites [12] source
The citation supports the exception for CRS and ICANS: the paper sets out consensus grading criteria for both in its ‘Consensus on CRS Grading (Table 2)’ and ‘Consensus on ICANS Grading for Adults’ sections (page not available). The citing study’s choice to grade its other adverse events using CTCAE v4.03 is not attributed to this source. (LLM, conf=0.93)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The primary end point of the phase 2 study was the overall response rate, which was defined as a partial response or better according to the criteria of the International Myeloma Working Group, as assessed by an independent review committee”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
What the sources say
- Partly supportedcites [10] sourceExperimental — accuracy not yet measured
The Response criteria section recommends IMWG criteria for clinical trials and endorses the IMWG definition of partial response; the Minimal response section also distinguishes partial response or better from minimal response. The paper does not establish that overall response rate was the primary endpoint of the particular phase 2 study or that an independent review committee assessed it (pages not provided). (LLM, conf=0.87)
- Not checked — no full text of the sourcecites [11] source
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Of the 19 deaths due to adverse events in our study, 12 were attributed to Covid-19, which was consistent with the higher mortality observed from Covid-19 in patients with hematologic cancers during this time frame.24”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Supportedcites [24] source
The citation supports the background comparison, not the citing authors’ own count of 12 COVID-19 deaths among 19 adverse-event deaths. The Discussion reports high COVID-19 mortality in patients with hematologic malignancies and says it was substantially higher than in the general population, while cautioning that the estimate may be elevated by the large proportion of hospitalized patients. (LLM, conf=0.92)
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“median, five previous therapy lines”
- Also stated in: § PATIENTS · plain
“Patients had received a median of 5 previous lines of therapy (range, 2 to 14)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > RESULTS
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § PATIENTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Teclistamab exposure was sustained over the predetermined target level (6 μg per milliliter, based on the upper boundary of an experimentally determined range of the 90% maximal effective concentration) with a low peak-to-trough ratio (Fig. S3).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytokine release syndrome occurred in 119 patients (72.1%). Most events occurred after step-up and cycle 1 doses, with 6 patients (3.6%) having cytokine release syndrome in cycle 2 or later. Most events of cytokine release syndrome were grade 1 or 2 in severity and fully resolved, except for one grade 3 event”
- Also stated in: § RESULTS · plain
“cytokine release syndrome (in 72.1% of the patients; grade 3, 0.6%; no grade 4)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 119Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were lower in patients with extramedullary disease, stage III disease, and at least 60% marrow replacement by plasma cells and were higher in those who had received no more than three previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“thrombocytopenia (in 66 [40.0%])”
- Also stated in: § RESULTS · plain
“thrombocytopenia (in 40.0%; grade 3 or 4, 21.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 66Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 68 patients (41.2%) died, with most deaths (41) attributed to progressive disease (Table S9). Nineteen patients died from adverse events, including 12 deaths from coronavirus disease 2019 (Covid-19). Five deaths were considered by investigators to be related to teclistamab”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, reductions in soluble BCMA levels occurred during the first 4 cycles of treatment in 63 of 72 evaluable patients (88%) who had a partial response or better, whereas all the evaluable patients who did not have a response (9 of 9 patients) had increased levels of soluble BCMA.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PHARMACOKINETICS, IMMUNOGENICITY, AND BIOMARKERS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“A total of 98 patients (59.4%) received at least 6 months of teclistamab treatment, and 79 patients (47.9%) received at least 9 months of treatment.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 98Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“All 165 patients reported having an adverse event (Table 2 and Table S5), which were grade 3 or 4 in 156 patients (94.5%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Five patients had a total of 9 events of immune effector cell–associated neurotoxicity syndrome, all either grade 1 or 2. Of these 9 events, 7 were concurrent with cytokine release syndrome, and all 9 events resolved without discontinuation or dose reduction.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“neutropenia (in 117 patients [70.9%])”
- Also stated in: § RESULTS · plain
“neutropenia (in 70.9%; grade 3 or 4, 64.2%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 117Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Injection-site reactions were reported in 60 patients (36.4%); all such events were grade 1 or 2.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 60Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the onset of cytokine release syndrome was 2 days (range, 1 to 6) after the most recent dose, and the median duration was 2 days (range, 1 to 9).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Investigator-assessed neurotoxic events, including immune effector cell–associated neurotoxicity syndrome, were reported in 24 patients (14.5%).”
- Also stated in: § RESULTS · plain
“Neurotoxic events occurred in 24 patients (14.5%), including immune effector cell–associated neurotoxicity syndrome in 5 patients (3.0%; all grade 1 or 2).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 24Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“anemia (in 86 [52.1%])”
- Also stated in: § RESULTS · plain
“anemia (in 52.1%; grade 3 or 4, 37.0%)”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 86Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median time until the first response was 1.2 months (range, 0.2 to 5.5), and the median time until a best response was 3.8 months (range, 1.1 to 16.8).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > EFFICACY
Strength:plain· not yet calibratedn = 165Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“One patient had a dose reduction during cycle 21 because of recurrent neutropenia, and 104 patients (63.0%) skipped a dose because of adverse events. Two patients discontinued teclistamab because of adverse events (grade 3 adenoviral pneumonia and grade 4 progressive multifocal leukoencephalopathy).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As of March 16, 2022, 70 patients (42.4%) were continuing to receive treatment (Fig. S1), with a median treatment duration of 8.5 months (range, 0.2 to 24.4).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > PATIENTS
Strength:plain· not yet calibratedn = 70Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Infections occurred in 126 patients (76.4%); 74 patients (44.8%) had grade 3 or 4 infections.”
- Also stated in: § RESULTS · plain
“Infections were frequent (in 76.4%; grade 3 or 4, 44.8%).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > RESULTS > SAFETY
Strength:plain· not yet calibratedn = 126Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § RESULTS · plain
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The overall depth of response was highlighted by the observation that 26.7% of the patients were found to have no minimal residual disease at a sensitivity level of 10−5; these patients made up 82% of those in whom minimal residual disease could be evaluated.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Cytopenias and infections were common; toxic effects that were consistent with T-cell redirection were mostly grade 1 or 2.”
- Also stated in: § DISCUSSION · plain
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > Abstract > CONCLUSIONS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § DISCUSSION · plain
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sponsor established a safety evaluation team to monitor patient safety throughout the phase 1 study. In phase 2, safety was monitored through continuous review by the sponsor.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, subgroup analyses suggest that patients who have received no more than three previous therapy lines may have a better response rate than those who have received more than three therapies, a finding that supports the use of teclistamab in earlier therapy lines (although the confidence intervals for this finding are wide).”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Teclistamab redirects CD3+ T cells to BCMA+ myeloma cells, resulting in T-cell activation and subsequent lysis and death of BCMA+ cells.18”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [18] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study was conducted in accordance with the principles of the Declaration of Helsinki and the Good Clinical Practice guidelines of the International Council for Harmonisation.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Toxic effects were also common but were mainly of low grade and reversible.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median relative dose intensity was high, and dose reductions and discontinuations owing to adverse events were infrequent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The safety and efficacy populations for this analysis included all the patients who had received at least one dose of teclistamab at the recommended phase 2 dose in phase 1 or phase 2 as of September 7, 2021.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Response rates were also compared across various prespecified subgroups, including those defined according to cytogenetic risk, refractory status, and number of previous lines of therapy.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“For phase 2, we determined that a sample size of 100 patients would provide a power of at least 85% to establish an overall response rate of more than 30% at a one-sided significance level of 0.025, assuming an overall response rate of at least 45%.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STATISTICAL ANALYSIS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Adverse events in this phase 1–2 trial were common and included low-grade cytokine release syndrome and grade 3 or 4 cytopenia and infection in a patient population that has an increased susceptibility to infection due to the immunodeficiency associated with myeloma and immunosuppressive effects of previous myeloma therapies.23”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [23] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Negativity for minimal residual disease was assessed by next-generation sequencing of DNA obtained from bone marrow aspirate (clonoSEQ assay, version 2.0 [Adaptive Biotechnologies]) with a threshold of 10−5 cells.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > END POINTS AND ASSESSMENTS
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The study protocol, amendments, and relevant documents were approved by the local independent ethics committee or institutional review board at each study site. All the patients provided written informed consent.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“All the authors affirm that the trial was conducted in accordance with the study protocol and vouch for the accuracy and completeness of the data.”
§ Teclistamab in Relapsed or Refractory Multiple Myeloma > METHODS > STUDY OVERSIGHT
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
The paper relies on this without support.
Teclistamab is readily available.
“Teclistamab is readily available and has been associated with rapid onset of response after a median of approximately 1 month of treatment.”
The paper relies on this without support.
No CD3-redirecting therapy has been approved for the treatment of myeloma.
“Although clinical proof of concept has been obtained for other CD3-redirection platforms in other indications,19-21 no CD3-redirecting therapy has been approved for the treatment of myeloma.”
The paper relies on this without support.
Cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations.
“Although cross-trial comparisons are challenging to interpret owing to differences in study design and patient populations, the response rates observed with teclistamab (63%) compare favorably with those of belantamab mafodotin”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“Two BCMA-targeting bispecific antibodies, teclistamab and elranatamab, have been approved for use in patients with relapsed myeloma who have received at least 4 prior regimens.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source doesn’t support the claim as written.
In the citing paper
“A number of BCMA-directed therapies, including belantamab mafodotin, idecabtagene vicleucel (ide-cel), ciltacabtagene autoleucel (cilta-cel) and teclistamab, have shown efficacy in clinical trials and are approved for the treatment of relapsed or refractory multiple myeloma4–9.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, patients with advanced disease stage (R-ISS stage III) have consistently shown poorer outcomes irrespective of the therapy received4–6,19–22.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In comparison to other BCMA-targeted T-cell-redirecting therapies, the rate of hematologic AEs with elranatamab was similar or lower after a similar follow-up4–6.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“and favorable to the BCMA-targeting antibody–drug conjugate, belantamab mafodotin (ORR 32%, median DOR 11.0 months and median PFS 2.8 months) after a median follow-up of 12.4 months4,9,19,23.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Experimental — accuracy not yet measured
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab and elranatamab are bispecific antibodies produce an immunotherapeutic effect by binding to BCMA on myeloma cells on one arm and CD3 on T cells with the other.91,92”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [91]
The cited source says what the claim attributes to it.
In the citing paper
“The primary endpoint in phase 2 was overall response rate per IMWG criteria,11 based on independent committee review, which was defined as the proportion of patients who had a partial response or better.”
From Safety and activity of talquetamab in patients with relapsed or refractory multiple myeloma (MonumenTAL-1): a multicentre, open-label, phase 1-2 study. (2025) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Teclistamab, a bispecific antibody targeting CD3×BCMA,6 demonstrated deep and durable responses in heavily pretreated RRMM in the phase 1/2 MajesTEC-1 study.7,8”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively),8 with most events being grade 1 and occurring during the step-up dosing schedule.”
From Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“In this trial, 165 RRMM patients were treated with Teclistamab, and the following key outcomes were observed 63.0% ORR, 58.8% VGPR, and 39.4% CR. These results demonstrate the significant clinical activity of Teclistamab in RRMM patients who have received multiple prior lines of therapy. The high ORR, VGPR rate, and CR rate indicate substantial anti-myeloma activity of Teclistamab. Additionally, t”
From Multiple myeloma: signaling pathways and targeted therapy (2024) · cites this paper as [209]
The cited source says what the claim attributes to it.
In the citing paper
“The lower response rate observed in patients with extramedullary disease reflects the historically poor prognosis in this subgroup and has also been observed with other anti-BCMA-targeted agents such as belantamab mafodotin and teclistamab4,19.”
From Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results (2023) · cites this paper as [4]
Citations
Cites
Lee, D. W., Santomasso, B. D., Locke, F. L., Ghobadi, A., Turtle, C. J., Brudno, J. N., Maus, M. V., Park, J. H., Mead, E., Pavletic, S., et al. (2019) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2018.12.758 · Cited by 3,675
Kumar, S., Paiva, B., Anderson, K. C., Durie, B., Landgren, O., Moreau, P., Munshi, N., Lonial, S., Bladé, J., Mateos, M.-V., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30206-6 · Cited by 3,061
Self-citationIdecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma.
Munshi, N. C., Anderson, L. D., Shah, N., Madduri, D., Berdeja, J., Lonial, S., Raje, N., Lin, Y., Siegel, D., Oriol, A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2024850 · Cited by 2,560
Self-citationBerdeja, J. G., Madduri, D., Usmani, S. Z., Jakubowiak, A., Agha, M., Cohen, A. D., Stewart, A. K., Hari, P., Htut, M., Lesokhin, A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00933-8 · Cited by 1,756
Self-citationRajkumar, S. V., Harousseau, J.-L., Durie, B., Anderson, K. C., Dimopoulos, M., Kyle, R., Blade, J., Richardson, P., Orlowski, R., Siegel, D., et al. (2011) · Blood · doi:10.1182/blood-2010-10-299487 · Cited by 1,036
Self-citationMultiple myeloma: EHA-ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up†
Dimopoulos, M. A., Moreau, P., Terpos, E., Mateos, M. V., Zweegman, S., Cook, G., Delforge, M., Hájek, R., Schjesvold, F., Cavo, M., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.014 · Cited by 900
Self-citationLonial, S., Lee, H. C., Badros, A., Trudel, S., Nooka, A. K., Chari, A., Abdallah, A.-O., Callander, N., Lendvai, N., Sborov, D., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30788-0 · Cited by 812
Self-citationVijenthira, A., Gong, I. Y., Fox, T. A., Booth, S., Cook, G., Fattizzo, B., Martín-Moro, F., Razanamahery, J., Riches, J. C., Zwicker, J., et al. (2020) · Blood · doi:10.1182/blood.2020008824 · Cited by 625
Shah, N., Chari, A., Scott, E., Mezzi, K., & Usmani, S. Z. (2020) · Leukemia · doi:10.1038/s41375-020-0734-z · Cited by 490
Self-citationBispecific T‐cell engagers for cancer immunotherapy
Huehls, A. M., Coupet, T. A., & Sentman, C. L. (2014) · Immunology and Cell Biology · doi:10.1038/icb.2014.93 · Cited by 478
Flagged first, then by citations
Cited by
Sorted by citations
Long-term outcomes following CAR T cell therapy: what we know so far
Cappell, K. M., & Kochenderfer, J. N. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00754-1 · Cited by 1,503
Antibody–drug conjugates come of age in oncology
Dumontet, C., Reichert, J. M., Senter, P. D., Lambert, J. M., & Beck, A. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00709-2 · Cited by 903
Talquetamab, a T-Cell–Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma
Chari, A., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Askari, E., Mateos, M.-V., Costa, L. J., Caers, J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2204591 · Cited by 744
Self-citationElranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results
Lesokhin, A. M., Tomasson, M. H., Arnulf, B., Bahlis, N. J., Miles Prince, H., Niesvizky, R., Rodrίguez-Otero, P., Martinez-Lopez, J., Koehne, G., Touzeau, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02528-9 · Cited by 664
“Includes t(4;14), t(14;16) and del(17p) chromosomal abnormalities.”
BackgroundSelf-citationMultiple myeloma: 2024 update on diagnosis, risk-stratification, and management
Rajkumar, S. V. (2024) · American Journal of Hematology · doi:10.1002/ajh.27422 · Cited by 534
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myeloma
Lee, H., Ahn, S., Maity, R., Leblay, N., Ziccheddu, B., Truger, M. S., Chojnacka, M., Cirrincione, A. M., Durante, M. A., Tilmont, R., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02491-5 · Cited by 370
Self-citationKaplon, H., Crescioli, S., Chenoweth, A. M., Visweswaraiah, J., & Reichert, J. M. (2022) · mAbs · doi:10.1080/19420862.2022.2153410 · Cited by 278
“Adverse events were consistent with this patient population and toxicities consistent with T-cell redirection were mostly Grade 1/2.(38) Teclistamab is being investigated also in combination studies, including the Phase 3 MajesTEC-3 (NCT05083169), MajesTEC-4 (NCT05243797), and MajesTEC-7 (NCT05552222) studies.”
BackgroundT-cell-engaging bispecific antibodies in cancer
van de Donk, N. W. C. J., & Zweegman, S. (2023) · The Lancet · doi:10.1016/s0140-6736(23)00521-4 · Cited by 275
Self-citationMailankody, S., Matous, J. V., Chhabra, S., Liedtke, M., Sidana, S., Oluwole, O. O., Malik, S., Nath, R., Anwer, F., Cruz, J. C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-022-02182-7 · Cited by 257
Self-citationProteomic signatures improve risk prediction for common and rare diseases
Carrasco-Zanini, J., Pietzner, M., Davitte, J., Surendran, P., Croteau‐Chonka, D. C., Robins, C., Torralbo, A., Tomlinson, C., Grünschläger, F., Fitzpatrick, N. K., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-03142-z · Cited by 254
Raje, N., Anderson, K., Einsele, H., Efebera, Y., Gay, F., Hammond, S. P., Lesokhin, A. M., Lonial, S., Ludwig, H., Moreau, P., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00879-7 · Cited by 209
“1% patients) received treatment with G-CSF [24].”
BackgroundResultInfluentialSelf-citationLudwig, H., Terpos, E., van de Donk, N. W. C. J., Mateos, M., Moreau, P., Dimopoulos, M. A., Delforge, M., Rodríguez‐Otero, P., Miguel, J. F. S., Yong, K., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00159-6 · Cited by 226
Self-citationBispecific T cell engager therapy for refractory rheumatoid arthritis
Bucci, L., Hagen, M., Rothe, T., Raimondo, M. G., Fagni, F., Tur, C., Wirsching, A., Wacker, J., Wilhelm, A., Auger, J.-P., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02964-1 · Cited by 199
“CD20 would be an alternative antigen—one that is already targeted by BiTEs such as mosunetuzumab and epcoritamab, studied in the treatment of lymphoma 26,27 .”
Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma
Bumma, N., Richter, J. R., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01008 · Cited by 191
“10, 19,20 Linvoseltamab was designed to have minimal immunogenicity and favorable molecular stability and pharmacokinetic (PK) properties.”
Self-citationEmerging therapies targeting the delta-like ligand 3 (DLL3) in small cell lung cancer
Rudin, C. M., Reck, M., Johnson, M. L., Blackhall, F. H., Hann, C. L., Yang, J. C., Bailis, J. M., Bebb, G. D., Goldrick, A., Umejiego, J., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01464-y · Cited by 186
Bispecific antibodies: advancing precision oncology
Herrera, M., Pretelli, G., Desai, J., Garralda, E., Siu, L. L., Steiner, T. M., & Au, L. (2024) · Trends in cancer · doi:10.1016/j.trecan.2024.07.002 · Cited by 193
Bispecific and multispecific antibodies in oncology: opportunities and challenges
Goebeler, M.-E., Stuhler, G., & Bargou, R. C. (2024) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-024-00905-y · Cited by 195
“MCLA-117, a full-length CLEC12A × CD3 IgG1 bispecific antibody is currently being tested in a phase I trial (NCT03038230).”
InfluentialDimopoulos, M., Terpos, E., Boccadoro, M., Moreau, P., Mateos, M., Zweegman, S., Cook, G., Engelhardt, M., Delforge, M., Hájek, R., et al. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01041-x · Cited by 188
“%) and neurotoxicity (14.5%, including ICANS in 3.0%, all of grade 1–2) 119,120 .”
InfluentialSelf-citationEmens, L. A., Romero, P. J., Anderson, A. C., Bruno, T. C., Capitini, C. M., Collyar, D. E., Gulley, J. L., Hwu, P., Posey, A. D., Silk, A. W., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009063 · Cited by 175
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects
Tang, L., Huang, Z., Mei, H., & Hu, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01521-5 · Cited by 181
“At present, CAR-T therapy has achieved remarkable results in R/R ALL, CLL, NHL, and MM. 37 There are many CAR targets for each malignant disease and the number of treatment lines is gradually advancing.”
BackgroundInfluentialElranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial
Bahlis, N. J., Costello, C. L., Raje, N. S., Levy, M. Y., Dholaria, B., Solh, M., Tomasson, M. H., Damore, M. A., Jiang, S., Basu, C., et al. (2023) · Nature Medicine · doi:10.1038/s41591-023-02589-w · Cited by 162
“8,9).”
Self-citationMultiple Myeloma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology
Kumar, S. K., Callander, N. S., Adekola, K., Anderson, L. D., Baljević, M., Baz, R., Campagnaro, E. L., Castillo, J. J., Costello, C. L., D'Angelo, C. R., et al. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2023.0061 · Cited by 174
Self-citationDimopoulos, M. A., Merlini, G., Bridoux, F., Leung, N., Mikhael, J. R., Harrison, S. J., Kastritis, E., Garderet, L., Gozzetti, A., van de Donk, N. W. C. J., et al. (2023) · The Lancet Oncology · doi:10.1016/s1470-2045(23)00223-1 · Cited by 170
Self-citationRodríguez‐Otero, P., Usmani, S. Z., Cohen, A. D., van de Donk, N. W. C. J., Leleu, X. P., Pérez‐Larraya, J. G., Manier, S., Nooka, A. K., Mateos, M., Einsele, H., et al. (2024) · The Lancet Oncology · doi:10.1016/s1470-2045(24)00043-3 · Cited by 157
Self-citationBCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
Hagen, M., Bucci, L., Boeltz, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2408786 · Cited by 142
Mazahreh, F., Mazahreh, L., Schinke, C., Thanendrarajan, S., Zangari, M., Shaughnessy, J. D., Zhan, F., van Rhee, F., & Al Hadidi, S. (2023) · Blood Advances · doi:10.1182/bloodadvances.2022009435 · Cited by 142
“5% of the patients (n = 123/165).(4) ABBV-383 was associated with hypogammaglobulinemia in 14% of the patients (n = 17/124).”
Lancman, G., Parsa, K., Kotlarz, K., Avery, L., Lurie, A., Lieberman-Cribbin, A., Cho, H. J., Parekh, S. S., Richard, S., Richter, J., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0049 · Cited by 140
Self-citationBi- and trispecific immune cell engagers for immunotherapy of hematological malignancies
Tapia‐Galisteo, A., Álvarez‐Vallina, L., & Sanz, L. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01482-w · Cited by 147
“Although response ratio was slightly lower than those in CAR-T-treated patients in previous clinical trials (67% for idecabtagene vicleucel y 83% for ciltacabtagene autoleucel), the greater safety profile based on lower CRS and neurotoxicity, along with the easier and faster manufacture, make teclistamab an alternativ…”
BackgroundRejeski, K., Hansen, D. K., Bansal, R., Sesques, P., Ailawadhi, S., Logue, J., Bräunlein, E., dos Santos, D. M. C., Freeman, C., Alsina, M., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01465-x · Cited by 140
D’Souza, A., Shah, N. D., Rodriguez, C., Voorhees, P. M., Weisel, K. C., Bueno, O. F., Pothacamury, R. K., Freise, K. J., Yue, S., Ross, J. A., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01504 · Cited by 134
“MR 1 (1) 1 (2) 1 (2) 1 (2) 2 (2) SD 18 (23) 17 (27) 14 (29) 13 (32) 36 (30)”
Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis
Reynolds, G. K., Cliff, E. R. S., Mohyuddin, G. R., Popat, R., Midha, S., Ng, M., Harrison, S. J., Kesselheim, A. S., & Teh, B. W. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023010539 · Cited by 134
Self-citationUnderstanding and overcoming multidrug resistance in cancer
Ge, M., Chen, X.-Y., Huang, P., Fleishman, J. S., Yang, D., Wu, Z., Ke, Z., & Chen, Z. (2025) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-025-01059-1 · Cited by 145
“For example, the bispecific BCMA × CD3 TCE teclistamab conferred durable responses in patients with heavily pretreated multiple myeloma in the phase I/II MajesTEC-1 trial, resulting in FDA Accelerated Approval for those who have received at least four prior lines of therapy 299 .”
Kaiser, M., Hall, A., Walker, K., Sherborne, A., de Tute, R., Newnham, N. J., Roberts, S., Ingleson, E., Bowles, K., Garg, M., et al. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.22.02567 · Cited by 90
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
Costa, L. J., Bahlis, N. J., Perrot, A., Nooka, A. K., Lu, J., Pawlyn, C., Mina, R., Caeiro, G., Kentos, A., Hungria, V., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2514663 · Cited by 119
“Cytokine release syndrome incidence was lower than that observed with teclistamab monotherapy in MajesTEC-1 (60.1% vs. 72.1%, respectively), 8 with most events being grade 1 and occurring during the step-up dosing schedule.”
InfluentialSelf-citationFerreri, C. J., Hildebrandt, M. A. T., Hashmi, H., Shune, L. O., McGuirk, J. P., Sborov, D. W., Wagner, C. B., Kocoglu, M. H., Rapoport, A. P., Atrash, S., et al. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00886-8 · Cited by 131
Self-citationChari, A., Touzeau, C., Schinke, C., Minnema, M. C., Berdeja, J. G., Oriol, A., van de Donk, N. W. C. J., Rodríguez-Otero, P., Morillo, D., Martinez-Chamorro, C., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00385-5 · Cited by 116
Self-citationReal-world analysis of teclistamab in 123 RRMM patients from Germany
Riedhammer, C., Bassermann, F. C., Besemer, B., Bewarder, M., Brunner, F., Carpinteiro, A., Einsele, H., Faltin, J., Frenking, J. H., Gezer, D., et al. (2024) · Leukemia · doi:10.1038/s41375-024-02154-5 · Cited by 132
Self-citationGPRC5D as a novel target for the treatment of multiple myeloma: a narrative review
Rodriguez-Otero, P., van de Donk, N. W. C. J., Pillarisetti, K., Cornax, I., Vishwamitra, D., Gray, K., Hilder, B., Tolbert, J., Renaud, T., Masterson, T., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-023-00966-9 · Cited by 113
“…T-cell – redirecting bispe-ci fi c antibodies compared with trials of BCMA-and Fc receptor-like protein 5 – targeting bispeci fi c antibodies [58 – 61], which may be due to the more limited expression pro fi le of GPRC5D in the immune compartment compared with the expression pro fi les of…”
Self-citationTeclistamab-Induced Remission in Refractory Systemic Lupus Erythematosus
Alexander, T., Krönke, J., Cheng, Q., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmc2407150 · Cited by 111
Davis, J. D., Padros, M. B., Conrado, D. J., Ganguly, S., Guan, X., Hassan, H. E., Hazra, A., Irvin, S. C., Jayachandran, P., Kosloski, M. P., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3150 · Cited by 124
Talquetamab plus Teclistamab in Relapsed or Refractory Multiple Myeloma
Cohen, Y. C., Magen, H., Gatt, M. E., Sébag, M., Kım, K., Min, C., Ocio, E. M., Yoon, S.-S., Chu, M. P., Rodríguez‐Otero, P., et al. (2025) · New England Journal of Medicine · doi:10.1056/nejmoa2406536 · Cited by 118
Self-citationTeclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study
Mohan, M., Monge, J., Shah, N. N., Luan, D., Forsberg, M., Bhatlapenumarthi, V., Balev, M., Patwari, A., Cheruvalath, H., Bhutani, D., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01003-z · Cited by 106
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma
Richardson, P. G. G., Trudel, S., Popat, R., Mateos, M., Vangsted, A. J., Ramasamy, K., Martínez‐López, J., Quach, H., Orlowski, R. Z., Arnao, M., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2303194 · Cited by 102
Self-citationFrerichs, K. A., Verkleij, C. P. M., Mateos, M., Martin, T. G., Rodriguez, C., Nooka, A. K., Banerjee, A., Chastain, K. M., Perales‐Puchalt, A., Stephenson, T., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011658 · Cited by 105
“1,41 Alongside prophylactic IVIG treatment in case of low IgG concentrations ( 4 g/L), additional strategies to prevent infections in patients treated with BCMA-targeting BsAbs are essential to reduce the burden of infectious complications, including the prophylactic use of granulocyte…”
BackgroundSelf-citationParikh, R. H., & Lonial, S. (2023) · CA A Cancer Journal for Clinicians · doi:10.3322/caac.21771 · Cited by 107
“gov identifier NCT04557098).(22,79) In addition to BCMA, studies are examining several other novel CAR T‐cell therapies for MM, with constructs targeted at CD19, CD38, SLAMF7, transmembrane activator and CAML interactor (TACI), and CD138.”
BackgroundNooka, A. K., Rodriguez, C., Mateos, M., Manier, S., Chastain, K. M., Banerjee, A., Kobos, R., Qi, K., Verona, R. I., Doyle, M., et al. (2023) · Cancer · doi:10.1002/cncr.35107 · Cited by 97
“25 In the primary safety analysis, infections occurred in 76.4% of patients, with grade 3/4 infections in 44.8%.”
BackgroundInfluentialSelf-citationBhatt, P. K., Kloock, C., & Comenzo, R. L. (2023) · Current Oncology · doi:10.3390/curroncol30020179 · Cited by 105
“At a follow-up of 14 months, ORR was 64%, with close to 40% of patients achieving a CR and sustaining these responses for a median of 18 months [153].”
BackgroundStrategies for clinical dose optimization of T cell-engaging therapies in oncology
Ball, K., Dovedi, S. J., Vajjah, P., & Phipps, A. (2023) · mAbs · doi:10.1080/19420862.2023.2181016 · Cited by 93
“In the FIH study for teclistamab, the subcutaneous dosing rationale was informed by modeling the early clinical IV PK data, and simulating the expected PK assuming a bioavailability of 60% after subcutaneous administration.(85)”
MethodGagelmann, N., Dima, D., Merz, M., Hashmi, H., Ahmed, N., Tovar, N., Oliver‐Caldés, A., Stölzel, F., Rathje, K., Fischer, L., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02232 · Cited by 96
Kang, C. (2022) · Drugs · doi:10.1007/s40265-022-01793-1 · Cited by 92
“Treatment with SC teclistamab was generally tolerable in patients with R/R MM, as demonstrated in the phase I/II MajesTEC-1 trial [1, 13].”
BackgroundMethodInfluentialMultiple myeloma: signaling pathways and targeted therapy
Lu, Q., Yang, D., Li, H., Niu, T., & Tong, A. (2024) · Molecular biomedicine · doi:10.1186/s43556-024-00188-w · Cited by 90
Bispecific antibodies in the treatment of multiple myeloma
Devasia, A. J., Chari, A., & Lancman, G. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01139-y · Cited by 94
“High tumor burden, as measured by bone marrow plasma cells >60%, ISS stage 3, and extra-medullary disease, has been shown to adversely impact the clinical ef fi cacy of BsAbs in MM [55, 62, 107, 108].”
BackgroundMethodInfluentialSelf-citationAdvances of Artificial Intelligence in Anti-Cancer Drug Design: A Review of the Past Decade
Wang, L., Song, Y., Wang, H., Zhang, X., Wang, M., He, J., Li, S., Zhang, L., Li, K., & Cao, L. (2023) · Pharmaceuticals · doi:10.3390/ph16020253 · Cited by 86
Holstein, S. A., Grant, S. J., & Wildes, T. M. (2023) · Journal of Clinical Oncology · doi:10.1200/jco.23.00512 · Cited by 93
Dima, D., Davis, J. A., Ahmed, N., Jia, X., Sannareddy, A., Shaikh, H. G., Shune, L. O., Kaur, G., Khouri, J., Afrough, A., et al. (2023) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2023.12.016 · Cited by 90
Fifty years of monoclonals: the past, present and future of antibody therapeutics
Chan, A. C., Martyn, G. D., & Carter, P. J. (2025) · Nature reviews. Immunology · doi:10.1038/s41577-025-01207-9 · Cited by 104
Mohan, M., Chakraborty, R., Bal, S., Nellore, A., Baljević, M., D’Souza, A., Pappas, P. G., Berdeja, J. G., Callander, N. S., & Costa, L. J. (2023) · British Journal of Haematology · doi:10.1111/bjh.18909 · Cited by 91
“5 The inclusion criteria of many T-cell directing therapy trials, which necessitate prior exposure to anti-CD38 monoclonal antibodies, is another contributing factor to the compromised production of normal immunoglobulins.”
BackgroundInfluentialGéraud, A., Hueso, T., Laparra, A., Bigé, N., Ouali, K., Cauquil, C. A., Stoclin, A., Danlos, F., Hollebecque, A., Ribrag, V., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.114075 · Cited by 91
Lee, H., Durante, M. A., Skerget, S., Vishwamitra, D., Benaoudia, S., Ahn, S., Poorebrahim, M., Barakat, E., Jung, D., Leblay, N., et al. (2024) · Blood · doi:10.1182/blood.2024026212 · Cited by 86
Self-citationXu, J., Wang, B., Yu, S., Chen, S., Yang, S., Liu, R., Chen, L., Hou, J., Chen, Z., Zhao, W., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01530-z · Cited by 89
Opportunities and limitations of B cell depletion approaches in SLE
Stockfelt, M., Teng, Y. K. O., & Vital, E. M. J. (2025) · Nature Reviews Rheumatology · doi:10.1038/s41584-024-01210-9 · Cited by 86
“Several of the patients showed grade 1–2 cytokine release syndrome, infections and hypogammaglob-ulinaemia, side effects that have previously been reported with the use of teclistamab in patients with multiple myeloma 108 .”
Costa, L. J., Banerjee, R. K., Mian, H. S., Weisel, K. C., Bal, S., Derman, B. A., Htut, M. M., Nagarajan, C., Rodriguez, C., Richter, J. R., et al. (2025) · Leukemia · doi:10.1038/s41375-024-02482-6 · Cited by 89
Self-citationMore Than 2% of Circulating Tumor Plasma Cells Defines Plasma Cell Leukemia–Like Multiple Myeloma
Jelínek, T., Bezděková, R., Žihala, D., Ševčíková, T., Sithara, A. A., Pospisilova, L., Ševčíková, S., Polackova, P., Štork, M., Knechtová, Z., et al. (2022) · Journal of Clinical Oncology · doi:10.1200/jco.22.01226 · Cited by 65
“Novel agents with possible activity in pPCLmight be considered.(29-33)”
BackgroundSelf-citationDerrien, J., Gastineau, S., Frigout, A., Giordano, N., Cherkaoui, M., Gaborit, V., Boinon, R., Douillard, E., Devic, M., Magrangeas, F., et al. (2023) · Nature Cancer · doi:10.1038/s43018-023-00625-9 · Cited by 77
“…5, member D (GPRC5D; talquetamab) demonstrated favorable safety profiles and promising efficacy in relapsed or refractory multiple myeloma (RRMM) in recent phase 1–2 studies 2,3 ; however, ~30% of patients did not respond and half of the responders experienced disease progression within 12 months.”
BackgroundSelf-citationVerkleij, C. P. M., O’Neill, C. A., Broekmans, M. E. C., Frerichs, K. A., Bruins, W. S. C., Duetz, C., Kruyswijk, S., Baglio, S. R., Skerget, S., Oca, R. M. D., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-3333 · Cited by 93
Self-citationLee, H., Neri, P. E., & Bahlis, N. J. (2024) · Blood · doi:10.1182/blood.2023022499 · Cited by 79
Self-citationMartin, T. G., Mateos, M., Nooka, A. K., Banerjee, A., Kobos, R., Pei, L., Qi, M., Verona, R. I., Doyle, M., Smit, J., et al. (2023) · Cancer · doi:10.1002/cncr.34756 · Cited by 73
“Therewere no grade4 or fatal events.(9)Here,we report in detail on CRS observed with teclistamab in MajesTEC‐1.”
BackgroundMethodInfluentialSelf-citationJourdes, A., Cellerin, E., Touzeau, C., Harel, S., Denis, B., Escure, G., Faure, E., Jamard, S., Danion, F., Sonntag, C., et al. (2024) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2024.02.023 · Cited by 77
Self-citationTomasson, M. H., Iida, S., Niesvizky, R., et al. (2024) · HemaSphere · doi:10.1002/hem3.136 · Cited by 72
Self-citationNooka, A. K., Cohen, A. D., Lee, H. C., Badros, A., Suvannasankha, A., Callander, N., Abdallah, A., Trudel, S., Chari, A., Libby, E. N., et al. (2023) · Cancer · doi:10.1002/cncr.34987 · Cited by 73
“The overall infection rates of 45%–55% in this study were lower in comparison to those for teclistamab (76% infection, 45% Grade 3– 4), 4 although the mPFS and duration of teclistamab treatment (11.3 and 8.5 months) are longer than belamaf in the overall study population.”
InfluentialSelf-citationTherapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 81
“Hematologic Teclistamab TECVAYLI BCMA, CD3 Humanized bispecific IgG4 Multiple myeloma [295] 2022 2022”
BackgroundTouzeau, C., Krishnan, A. Y., Moreau, P., Perrot, A., Usmani, S. Z., Manier, S., Cavo, M., Chamorro, C. M., Nooka, A. K., Martin, T. G., et al. (2024) · Blood · doi:10.1182/blood.2023023616 · Cited by 71
Self-citationAl-Qazaqi, R. A., Schinke, C., Thanendrarajan, S., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.28877 · Cited by 65
Cortés‐Selva, D., Perova, T., Skerget, S., Vishwamitra, D., Stein, S. J., Boominathan, R., Lau, O., Calara-Nielsen, K., Davis, C., Patel, J., et al. (2024) · Blood · doi:10.1182/blood.2023022823 · Cited by 73
Self-citationRadtke, K. K., Bender, B. C., Li, Z., Turner, D. C., Roy, S., Belousov, A., & Li, C. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-2247 · Cited by 75
John, M., Helal, M., Duell, J., Mattavelli, G., Stanojkovska, E., Afrin, N., Leipold, A. M., Steinhardt, M., Zhou, X., Žihala, D., et al. (2024) · Blood · doi:10.1182/blood.2024024590 · Cited by 73
Scott, S. A., Marin, E. M., Maples, K. T., Joseph, N. S., Hofmeister, C. C., Gupta, V. A., Dhodapkar, M. V., Kaufman, J. L., Lonial, S., & Nooka, A. K. (2023) · Blood Cancer Journal · doi:10.1038/s41408-023-00963-y · Cited by 63
“The median duration of response (DOR) was 18.4 months, median progression free survival (PFS) was 11.3 months, and median overall survival (OS) was 18.3 months [2].”
BackgroundResultInfluentialSelf-citationCAR T-Cell Therapy for Patients with Multiple Myeloma: Current Evidence and Challenges
Rendo, M. J., Joseph, J. J., Phan, L. M., & DeStefano, C. B. (2022) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s327016 · Cited by 68
“However, compared to the BCMA T-cell redirecting bispecific antibody teclistamab, ide-cel and cilta-cel appear to induce deeper responses with similar rates of PFS.(61)”
ResultYin, N., Li, X., Zhang, X., Xue, S., Cao, Y., Niedermann, G., Lu, Y., & Xue, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01826-z · Cited by 74
Antigen escape as a shared mechanism of resistance to BCMA-directed therapies in multiple myeloma
Firestone, R., Socci, N. D., Shekarkhand, T., Zhu, M., Qin, W. G., Hultcrantz, M. L., Mailankody, S., Tan, C. R. C., Korde, N., Lesokhin, A. M., et al. (2024) · Blood · doi:10.1182/blood.2023023557 · Cited by 72
Self-citationLim, E. A., Schweizer, M. T., Chi, K. N., Aggarwal, R., Agarwal, N., Gulley, J., Attiyeh, E., Greger, J., Wu, S., Jaiprasart, P., et al. (2023) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2023.02.010 · Cited by 62
Stadler, C., Ellinghaus, U., Fischer, L., Bähr-Mahmud, H., Rao, M., Lindemann, C., Chaturvedi, A., Scharf, C., Biermann, I., Hebich, B., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adl2720 · Cited by 70
Bispecific antibodies in multiple myeloma treatment: A journey in progress
Cho, S., Yeh, T., Anderson, K. C., & Tai, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1032775 · Cited by 63
“5%), and no patients discontinued teclistamab treatment because of neurotoxicity (44).”
BackgroundHammons, L. R., Szabó, A., Janardan, A., Bhatlapenumarthi, V., Annyapu, E., Dhakal, B., Hadidi, S. A., Radhakrishnan, S. V., Narra, R. K., Bhutani, D., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283590 · Cited by 61
“15 Furthermore, BCMA targeting bsAb cause almost universal profound and prolonged hypogammaglobinemia, cytopenias (neutropenia and lymphopenia) 1 and T-cell exhaustion especially with continuous therapy.”
BackgroundResultInfluentialvan de Donk, N. W. C. J., Chari, A., & Mateos, M. (2024) · The Lancet Haematology · doi:10.1016/s2352-3026(24)00186-8 · Cited by 65
Self-citationStepping forward: T-cell redirecting bispecific antibodies in cancer therapy
Qin, X., Ning, W., Liu, H., Liu, X., Luo, W., & Xia, N. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.027 · Cited by 62
“In the dose-escalation phase I trial, 29 subjects were enrolled, with a dose range of 0.003 e 0.81 m g/kg 37 e 39 .”
BackgroundMethodInfluentialClinical development of immuno-oncology therapeutics
Wang, J., Chen, Q., Shan, Q., Liang, T., Forde, P. M., & Zheng, L. (2025) · Cancer Letters · doi:10.1016/j.canlet.2025.217616 · Cited by 60
Girgis, S., Lin, S. X. W., Pillarisetti, K., Verona, R. I., Vieyra, D. S., Casneuf, T., Fink, D., Miao, X., Chen, Y., Stephenson, T., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007625 · Cited by 55
“Similar findings were observed at the RP2D in MajesTEC-1.(17) sBCMA also seemed to be a marker of responses to talquetamab, suggesting that it is a useful potential surrogate marker of response irrespective of the target.”
ResultSelf-citationLAG-3 Inhibitors: Novel Immune Checkpoint Inhibitors Changing the Landscape of Immunotherapy
Ibrahim, R., Saleh, K., Chahine, C., Khoury, R., Khalife, N., & Cesne, A. L. (2023) · Biomedicines · doi:10.3390/biomedicines11071878 · Cited by 60
“To date, bispecific antibodies are mainly approved in hematologic malignancies such as teclistamab in multiple myeloma and glofitamab in diffuse large B-cell lymphoma [101,102].”
BackgroundBispecific Antibodies in Hematological Malignancies: A Scoping Review
Omer, M. H., Shafqat, A., Ahmad, O., AlKattan, K. M., Yaqinuddin, A., & Damlaj, M. (2023) · Cancers · doi:10.3390/cancers15184550 · Cited by 60
“Adverse events included grade 1–2 CRS, cytopenias, and infections [32].”
BackgroundInfluentialPerspectives on the Treatment of Multiple Myeloma
Rafae, A., van Rhee, F., & Hadidi, S. A. (2023) · The Oncologist · doi:10.1093/oncolo/oyad306 · Cited by 65
Clinical management of patients with relapsed/refractory multiple myeloma treated with talquetamab
Chari, A., Krishnan, A., Rasche, L., Ye, J. C., Garfall, A., Popat, R., Lipe, B., Qin, X., Campagna, M., Masterson, T., et al. (2024) · Clinical Lymphoma Myeloma and Leukemia · doi:10.1016/j.clml.2024.05.003 · Cited by 53
Self-citationMarkouli, M., Ullah, F., Unlu, S., Omar, N., Lopetegui-Lia, N., Duco, M. R., Anwer, F., Raza, S., & Dima, D. (2023) · Current Oncology · doi:10.3390/curroncol30070467 · Cited by 51
“The most common AE of TEC in the MajesTEC-1 trial was HT, with neutropenia (71%), anemia (52%), and thrombocytopenia (40%) [5].”
BackgroundInfluentialMinimal Residual Disease in Multiple Myeloma: Past, Present, and Future
Medina-Herrera, A., Sarasquete, M., Jiménez, C., Puig, N., & García-Sánz, R. (2023) · Cancers · doi:10.3390/cancers15143687 · Cited by 56
“7%) showed MRD negativity by NGS at 10−5 with teclistamab [95].”
BackgroundCD8 effector T cells enhance teclistamab response in BCMA-exposed and -naïve multiple myeloma
Firestone, R., McAvoy, D. P., Shekarkhand, T., Serrano, E., Hamadeh, I. S., Wang, A., Zhu, M., Qin, W. G., Patel, D., Tan, C. R. C., et al. (2023) · Blood Advances · doi:10.1182/bloodadvances.2023011225 · Cited by 53
Self-citationTeclistamab in relapsed or refractory AL amyloidosis: a multinational retrospective case series
Forgeard, N., Elessa, D., Carpinteiro, A., et al. (2023) · Blood · doi:10.1182/blood.2023022937 · Cited by 53
Self-citationImpact of extramedullary multiple myeloma on outcomes with idecabtagene vicleucel
Zanwar, S., Sidana, S., Shune, L. O., Puglianini, O. A. C., Pasvolsky, O., Gonzalez, R. M., Dima, D., Afrough, A., Kaur, G., Davis, J. A., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-024-01555-4 · Cited by 59
“Immune effector therapies, including CAR-T and bispecific antibodies, have demonstrated excellent response rates ranging from 60 to 90% in heavily pretreated population of patients with MM [6, 24–27].”
BackgroundSelf-citationFandrei, D., Seiffert, S., Rade, M., Rieprecht, S., Gagelmann, N., Born, P., Wiemers, T. C., Weidner, H., Kreuz, M., Schassberger, T., et al. (2024) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-24-0118 · Cited by 53
The emerging therapeutic landscape of relapsed/refractory multiple myeloma
Tanenbaum, B., Miett, T., & Patel, S. A. (2022) · Annals of Hematology · doi:10.1007/s00277-022-05058-5 · Cited by 57
Letouzé, É., Moreau, P., Munshi, N. C., Samur, M., Minvielle, S., & Touzeau, C. (2024) · Blood Advances · doi:10.1182/bloodadvances.2023012354 · Cited by 53
“6 This could be done by cytometry or single-cell RNA/variable diversity joining (VDJ) sequencing.”
Self-citation
Metadata
- Authors
- Moreau, P., Garfall, A. L., van de Donk, N. W. C. J., Nahi, H., San-Miguel, J. F., Oriol, A., Nooka, A. K., Martin, T., Rosinol, L., Chari, A., Karlin, L., Benboubker, L., Mateos, M.-V., Bahlis, N., Popat, R., Besemer, B., Martínez-López, J., Sidana, S., Delforge, M., Pei, L., Trancucci, D., Verona, R., Girgis, S., Lin, S. X. W., Olyslager, Y., Jaffe, M., Uhlar, C., Stephenson, T., Van Rampelbergh, R., Banerjee, A., Goldberg, J. D., Kobos, R., Krishnan, A., & Usmani, S. Z.
- Affiliations
- Karolinska University Hospital (SE)
- From the Hematology Clinic, University Hospital Hôtel-Dieu, Nantes (P.M.), Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, Pierre-Bénite (L.K.), and Service d’Hématologie et Thérapie Cellulaire, Hôpital Bretonneau, Centre Hospitalier Régional Universitaire, Tours (L.B.) — all in France; Abramson Cancer Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia (A.L.G.), and Janssen Research and Development, Spring House (R.V., S.G., S.X.W.L., C.U., T.S., A.B.) — both in Pennsylvania; the Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Cancer Center Amsterdam, Amsterdam (N.W.C.J.D.); Karolinska University Hospital at Huddinge, Stockholm (H.N.); Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada, Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Instituto de Investigación Sanitaria de Navarra, Pamplona (J.F.S.-M.), Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Puj...
- City Of Hope National Medical Center (US)
- Memorial Sloan Kettering Cancer Center (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2022-08-11
- Volume
- 387
- Issue
- 6
- Pages
- 495-505
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC10587778
- OpenAlex
- W4282033105
- Cited by
- 1,269
- References
- 25
- Citations by year
- 2026: 335 · 2025: 341 · 2024: 320 · 2023: 231 · 2022: 39
- FWCI
- 169.47
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Lirias (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Janssen Research & Development, LLC
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Immunology and Microbiology › Immunology › Monoclonal and Polyclonal Antibodies Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- teclistamab, relapsed/refractory multiple myeloma, bispecific T-cell engagers, overall response rate, minimal residual disease negativity, progression-free survival, cytokine release syndrome, neurotoxicity, dose-limiting toxicity, subcutaneous administration, immunotherapy safety and efficacy
- MeSH terms
- Antineoplastic Agents, Immunological, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Humans, Injections, Subcutaneous, Multiple Myeloma, Neoplasm Recurrence, Local, Recurrence, T-Lymphocytes, CD3 Complex, Antibodies, Bispecific, B-Cell Maturation Antigen, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-12, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-12 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
